导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.93% | 1307/4773 |
| 近一周 | -1.87% | 809/5462 |
| 近一月 | -4.56% | 2564/5421 |
| 近一季 | -7.25% | 2345/5209 |
| 近半年 | -1.53% | 1621/4920 |
| 近一年 | 7.40% | 1313/4366 |
| 近两年 | 58.75% | 1246/2954 |
| 近三年 | 37.05% | 795/2253 |
| 成立以来 | 151.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.26% 1742/4961 |
16.15% 1595/5312 |
- - |
- - |
| 2025 | 23.28% 1887/4813 |
-0.38% 2223/3635 |
2.16% 1809/4076 |
20.32% 1996/4524 |
0.67% 1852/4813 |
| 2024 | 13.90% 1097/3463 |
1.51% 877/2808 |
-1.99% 1127/3014 |
16.44% 1456/3129 |
-1.68% 1791/3463 |
| 2023 | -7.34% 909/2656 |
5.54% 775/2280 |
-3.80% 906/2385 |
-3.16% 858/2515 |
-5.77% 1499/2655 |
| 2022 | -18.32% 689/2207 |
-13.69% 815/1919 |
6.51% 682/2016 |
-12.99% 815/2113 |
2.11% 1035/2208 |
| 2021 | 8.46% 476/1822 |
-2.96% 731/1255 |
8.29% 639/1330 |
0.23% 467/1466 |
2.98% 489/1822 |
| 2020 | 38.81% 348/1250 |
-6.94% 517/1028 |
15.12% 515/1067 |
14.80% 254/1164 |
12.86% 420/1184 |
| 2019 | 42.90% 200/1092 |
27.52% 343/754 |
-1.03% 293/804 |
5.03% 168/850 |
7.81% 394/918 |
| 2018 | -23.10% 268/834 |
- - |
- - |
- - |
-11.39% 291/691 |
| 2017 | 16.43% 237/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.29% 301/605 |
- - |
- - |
- - |
- - |
| 2015 | 16.64% 134/575 |
- - |
- - |
- - |
- - |
| 2014 | 36.66% 140/237 |
- - |
- - |
- - |
- - |
| 2013 | -1.25% 67/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.27% 85/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 长盛同庆中证800(LOF) VS. 长安沪深300非周期A(740101) |